We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+5.06%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$11.8B
AUM Growth
+$261M
Cap. Flow
+$368M
Cap. Flow %
3.12%
Top 10 Hldgs %
80.71%
Holding
127
New
5
Increased
21
Reduced
20
Closed
13

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$268M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$210M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$46.6M
4
HRTX icon
Heron Therapeutics
HRTX
+$44.6M
5
ACGN
Aceragen Inc
ACGN
+$41M

Top Sells

Rank Stock Value
1
ABLX
Ablynx NV
ABLX
+$98.3M
2
RXDX
Ignyta, Inc.
RXDX
+$37M
3
IMGN
Immunogen Inc
IMGN
+$16.4M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$10.8M
5
ANAB icon
AnaptysBio
ANAB
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 93.85%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBAY
26
DELISTED
Cymabay Therapeutics
CBAY
$50.9M 0.43%
3,917,700
+925,925
+31% +$11.5M
RYTM icon
27
Rhythm Pharmaceuticals
RYTM
$7.31B
$40.8M 0.35%
2,049,020
– –
NVTA
28
DELISTED
Invitae Corporation
NVTA
$39.4M 0.33%
8,399,411
+1,111,111
+15% +$7.93M
BLUE
29
DELISTED
bluebird bio
BLUE
$34.1M 0.29%
15,440
– –
ABEO icon
30
Abeona Therapeutics
ABEO
$355M
$31.3M 0.27%
87,375
+8,000
+10% +$2.97M
HALO icon
31
Halozyme
HALO
$9.88B
$31M 0.26%
1,581,424
– –
SGMO
32
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$30.5M 0.26%
1,607,579
-505,797
-24% -$10.8M
NKTR icon
33
Nektar Therapeutics
NKTR
$2.39B
$29.3M 0.25%
18,360
+6,898
+60% +$8.89M
BLCM
34
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$27.2M 0.23%
415,158
-88,073
-18% -$6.65M
VYNE icon
35
VYNE Therapeutics
VYNE
$26.3M 0.22%
+194
New +$23.6M
XNCR icon
36
Xencor
XNCR
$1.45B
$26.1M 0.22%
872,072
– –
LKFT
37
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$25.9M 0.22%
259,894
– –
EXEL icon
38
Exelixis
EXEL
$13.9B
$25.8M 0.22%
1,162,644
-343,855
-23% -$9.5M
GWPH
39
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$25M 0.21%
221,800
– –
MRUS
40
DELISTED
Merus
MRUS
$21.5M 0.18%
1,160,014
– –
AIMT
41
DELISTED
Aimmune Therapeutics
AIMT
$21.4M 0.18%
673,908
– –
ECYT
42
DELISTED
Endocyte, Inc. Common Stock
ECYT
$20.7M 0.18%
2,277,799
+1,190,476
+109% +$6.57M
NTLA icon
43
Intellia Therapeutics
NTLA
$1.51B
$17.6M 0.15%
833,795
-311,658
-27% -$7.66M
PGNX
44
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$17.2M 0.15%
2,306,184
-844,624
-27% -$5.62M
INSM icon
45
Insmed
INSM
$22.4B
$15.8M 0.13%
700,000
– –
MYOK
46
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$14.2M 0.12%
290,264
-65,000
-18% -$3.38M
BOLD
47
DELISTED
Audentes Therapeutics, Inc
BOLD
$11.8M 0.1%
+393,222
New +$13.3M
QURE icon
48
uniQure
QURE
$2.75B
$11.8M 0.1%
500,000
+17,443
+4% +$380K
AERI
49
DELISTED
Aerie Pharmaceuticals
AERI
$11.7M 0.1%
215,655
-83,701
-28% -$4.68M
CFRX
50
DELISTED
ContraFect Corporation
CFRX
$11.6M 0.1%
8,941
– –
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2018 Portfolio in Review

As of Q1 2018, Baker Bros. Advisors held 127 positions worth $11.8B, up 2.3% from $11.5B the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Baker Bros. Advisors deployed $368M of net new capital in Q1 2018, opening 5 new positions and adding to 21 existing holdings. Its largest new stake was VYNE Therapeutics: 194 shares worth $26.3M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Ablynx NV, an estimated $98.3M trimmed.

  • Baker Bros. Advisors's largest Q1 2018 buy was VYNE Therapeutics: 194 shares worth $26.3M.
  • Baker Bros. Advisors added most to BeOne Medicines Ltd in Q1 2018, an estimated $268M increase.
  • Baker Bros. Advisors's biggest Q1 2018 reduction was Ablynx NV, cutting an estimated $98.3M.
  • Baker Bros. Advisors fully exited Ignyta, Inc. in Q1 2018, selling an estimated $37M.
  • Baker Bros. Advisors's ten largest holdings make up 81% of its $11.8B portfolio in Q1 2018.
  • Baker Bros. Advisors opened 5 new positions and closed 13 in Q1 2018.
  • Baker Bros. Advisors's portfolio value rose 2.3% quarter-over-quarter to $11.8B.

Based on Baker Bros. Advisors's 13F filing for Q1 2018, filed 15 May 2018.